$SEPN

Shaikhly Samira sold $172K of SEPN

Shaikhly Samira (Chief People Officer) sold 5,935 shares of Septerna, Inc. (SEPN) at an average of $28.93 ($27.78–$29.66, $0.17M total) across 3 trades on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Shaikhly Samira
Published Jun 3, 2026, 11:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:48 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SEPN
Bearish
medium confidence
Mentioned
$SEPN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SEPNBearishLow
01

Why it matters

Provides fresh data on insider activity for SEPN, useful for short‑term traders.

02

Market read

Small insider sale with limited price impact; primarily of interest to short‑term traders monitoring insider activity.

03

What to watch

Potential upcoming compensation grant or tax planning could be driving the sale.

Relevance 3/10Novelty 3/10Timing: filing date 2026‑06‑03

Background

SEC Form 4 filing discloses insider transactions required by regulation.

Company-level read

Ticker impact

$SEPNBearishMedium confidence
Context

Chief People Officer Shaikhly Samira sold 5,935 shares for $171.7K via a 10b5‑1 plan.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

Sale size is small relative to market cap, but insider sales often trigger brief sell‑offs.

Market effects

Minimal impact on the broader HR tech sector.

No significant regional effect.

Limited to SEPN investors.

Counterpoint

The sale could be routine liquidity management, not a negative signal.

Key entities

  • Septerna, Inc.

    Issuer of the Form 4 filing.

  • Shaikhly Samira

    Chief People Officer and insider seller.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SEPNMed

Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results

Septerna, Inc. (SEPN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results Phase 1 Clinical Trial Ongoing for SEP-479, an Oral Small Molecule PTH1R Agonist SEP-479 Observed Clinical Pharmacokinetic Profile Supports Once-Daily Dosing; SAD / MAD Data Expec